The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: Effects with fluoxetine and paroxetine versus sertraline

Journal of Psychiatric Practice

Volumn 13, Issue 1, 2007, Pages 5-12

  Preskorn, Sheldon H ^a,e   Shah, Rozina ^b   Neff, Melissa ^c   Golbeck, Amanda L ^d   Choi, Joe ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Vet Integrated Service Network 15   (United States)

^d UNIVERSITY OF MONTANA   (United States)

^e University of Montreal   (United States)

Author keywords

Antidepressants; Cytochrome P450 enzymes; Drug interactions; Fluoxetine; Medication errors; Multiple medication use; Paroxetine; Polypharmacy; Prescribing practices; Sertraline; Veterans Affairs

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; BENZATROPINE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLARITHROMYCIN; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DILTIAZEM; DOXEPIN; ERYTHROMYCIN; ESCITALOPRAM; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; INDINAVIR; NIFEDIPINE; NORTRIPTYLINE; PAROXETINE; PHENYLPROPANOLAMINE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERBINAFINE; TRAZODONE; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; DEPRESSION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG METABOLISM; HUMAN; PRESCRIPTION; SIDE EFFECT; VETERAN;

CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MEDICATION ERRORS; MIDDLE AGED; PAROXETINE; RETROSPECTIVE STUDIES; RISK; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; VETERANS;

EID: 33846434461     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200701000-00002     Document Type: Article

References (24)

1. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. JAMA 2002;287:337-44.
2. Preskorn SH, Silkey B, Shah R, et al. Complexity of outpatient medication use in the Veterans Affairs healthcare system: Part I. Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005;11:5-15.
3. Silkey B, Preskorn SH, Golbeck A, et al. Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract 2005;11:16-26.
4. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001;161:1629-34.
5. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-15.
6. Hanlon JT, Fillenbaum GG, Schmader KE, et al. Inappropriate drug use among community-dwelling elderly. Pharmacotherapy 2000;20:575-82.
7. Goulding MR. Inappropriate medication prescribing for elderly ambulatory care patients. Arch Int Med 2004;164:305-12.
8. Hanlon JT, Artz MB, Pieper CF, et al. Inappropriate medication use among frail elderly inpatients. Ann Pharmacother 2004;38:9-14.
9. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994;272:292-6.
10. Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. Arch Intern Med 1999;159:2553-60.
11. Kazis LE, Ren XS, Lee A, et al. Health status in VA patients: Results from the Veterans Health Study. Am J Med Qual 1999;14:28-38.
12. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
13. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (Part I). J Pract Psychiatry 2003;9:150-8 (Can be accessed at www.preskorn.com).
14. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (Part II). J Pract Psychiatry 2003;9:228-36 (Can be accessesd at www.preskorn.com).
15. Preskorn SH, Greenblatt DJ, Flockhart DA, et al. Comparison of duloxetine, escitalopram and sertraline effects on cytochrome P45O (CYP) 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007;27:28-34.
16. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, OK: Professional Communications; 1996.
17. Preskorn SH. Outpatient management of depression: A guide for the primary-care practitioner. Caddo, OK: Professional Communications; 1999.
18. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol 1996;16:273-85.
19. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 1996;16:345-55.
20. Madsen H, Enggaard TP, Hansen LL, et al. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001;69:41-7.
21. Beardon PH, McGilchrist MM, McKendrick AD, et al. Primary noncompliance with prescribed medication in primary care. BMJ 1993;307:846-8.
22. Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: Phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990;10:88-95.
23. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
24. The Joint Commission. Using medication reconciliation to prevent errors. Sentinel Event Alert Issue 35, January 25, 2006. (Available at www.jointcommission.org/SentinelEvents/SentinelEventAlert/sea_35.htm, accessed January 9, 2007.)